泰恩康(301263.SZ):華鉑凱盛的鹽酸毛果芸香鹼滴眼液III期臨牀試驗完成首例受試者入組
格隆匯6月26日丨泰恩康(301263.SZ)公佈,近日,廣東泰恩康醫藥股份有限公司全資子公司山東華鉑凱盛生物科技有限公司(簡稱“華鉑凱盛”)組織開展的鹽酸毛果芸香鹼滴眼液用於成人老視患者的III期臨牀試驗完成首例受試者入組。
鹽酸毛果芸香鹼滴眼液III期臨牀試驗為用於成人老視患者的有效性和安全性的隨機、多中心、雙盲、安慰劑對照臨牀試驗,由首都醫科大學附屬北京同仁醫院眼科主任、享受國務院政府特殊津貼專家接英教授牽頭,全國10餘家臨牀研究中心參研,評價鹽酸毛果芸香鹼滴眼液(1.25%)用於成人老視患者的有效性和安全性。
鹽酸毛果芸香鹼是M-膽鹼受體激動劑,可激活平滑肌(例如虹膜括約肌和睫狀肌)的毒蕈鹼受體,通過虹膜括約肌的收縮,使瞳孔收縮,以增加焦深,改善近中視力,同時保持瞳孔對光的反應,另外其還可收縮睫狀肌,增強適應力,從而達到治療成人老視的效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.